Working… Menu

Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00154375
Recruitment Status : Completed
First Posted : September 12, 2005
Results First Posted : February 2, 2011
Last Update Posted : April 26, 2011
Information provided by:

Brief Summary:
This is a Phase III study comparing Imatinib mesylate and hydroxyurea combination therapy with hydroxyurea monotherapy in patients with temozolomide resistant progressive glioblastoma.

Condition or disease Intervention/treatment Phase
Glioblastoma Multiforme Astrocytoma Drug: Imatinib mesylate Drug: Hydroxyurea Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 240 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase III Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma
Study Start Date : October 2004
Actual Primary Completion Date : August 2008

Arm Intervention/treatment
Experimental: Imatinib mesylate + hydroxyurea (HU)
Imatinib was supplied as 100 mg and 400 mg tablets. Patients in the combination arm were instructed to take a daily oral imatinib dose of 600 mg (600 mg at lunch time) and a daily oral hydroxyurea (HU) dose of 1000 mg (500 mg twice daily; in the morning and at bed time). Every 6 weeks after randomization based on assessment of therapeutic response, either patients continued with above mentioned dosing regimen or switched to receive a daily dose of 800 mg imatinib with 1000 mg HU. Patients were instructed to split the intake, taking 400 mg imatinib with 500 mg HU in the morning, then the same in the evening.
Drug: Imatinib mesylate
Imatinib was supplied as 100 mg and 400 mg tablets packaged in polyethylene bottles.
Other Name: Glivec®

Drug: Hydroxyurea
Other Name: Litalir®

Active Comparator: Hydroxyurea alone
1500 mg/day of HU given as 500 mg 3 times daily. Every 6 weeks after randomization and based on assessment of therapeutic response, the patients were either switched to combination arm or continued in monotherapy arm of hydroxyurea.
Drug: Hydroxyurea
Other Name: Litalir®

Primary Outcome Measures :
  1. Percentage of Participants With Progression Free Survival (PFS) During the Study Duration [ Time Frame: 6 months -1 year ]
    PFS was defined as the time from the date of randomization to the date of the first documented progression according to the MacDonald criteria, or death due to any cause. MacDonald criteria are standard criteria in neurooncology. Tumor assessment was made according to the adapted MacDonald criteria based on the combined evaluation of 1) assessment of the MRI scan for measurable, evaluable, and new lesions (made by the independent external expert too), 2) overall assessment of neurological performance (made by the investigator), 3) concomitant steroid use (as reported by the investigator).

Secondary Outcome Measures :
  1. Number of Participants With Death, Other Serious or Clinically Significant Adverse Events (AEs) or Related Discontinuations [ Time Frame: 6 months - 1 year ]
    National Cancer Institute (NCI)/ National Institute of Health (NIH) provides a grading (severity) scale for each AE term. Grade 3 refers to severe AE and Grade 4 refers to life-threatening or disabling AE. According to FDA 21CFR 314.80, a serious adverse event (SAE) is described as any adverse event that leads to death, is life threatening ( NIH criteria Grade 4), causes or prolongs hospitalization, results in a congenital anomaly, or any other important medical event not described above.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Signed informed consent prior to initiation of any study procedure.
  • Patients >= 18 years of age.
  • Histological confirmed diagnosis of glioblastoma multiforme / astrocytoma World Health Organization (WHO) grade IV by a reference pathologist
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2.
  • Adequate hepatic, renal and bone marrow function as defined by the following: total bilirubin < 1.5 x Upper Limit of Normal (ULN), ALT and AST < 2.5 x ULN, creatinine < 1.5 x ULN, absolute neutrophil count > 1.5 x109/L, platelets > 100 x109/L and hemoglobin > 10 g/dL.
  • Female patients of childbearing potential with a negative pregnancy test within 7 days of initiation of study drug dosing. Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Male and female patients of reproductive potential who agree to employ an effective barrier method of birth control throughout the study, and for up to 3 months following discontinuation of study drug.
  • Life expectancy of >3 months.
  • MRI available every 6 weeks for disease management
  • No intercerebral inflammation
  • Irradiation therapy 54 to 62 gy finished or less according to national standard
  • Chemotherapy at least 1 temozolomide containing regimen finished, no established chemotherapy regiment available and progression under chemotherapy or in between 6 months following the last chemotherapy.
  • Leucocytes > 2.500/µl, to be controlled once a week
  • Thrombocytes > 80.000/µl, to be controlled once a week
  • Ensured compliance
  • Patients who had a second or third resection after disease progression cannot be included earlier than 2 weeks following the resection. MRI should be performed not later than 72 h post operation. If patients are to be included later than 4 weeks after the resection, a new baseline MRI must be performed.

Exclusion Criteria:

  • Female patients who are pregnant or breast-feeding.
  • Patients who have been treated with any investigational agent(s) within 28 days of the first day of administration of study drug.
  • Patients with uncontrolled medical disease such as diabetes mellitus, thyroid dysfunction, neuropsychiatric disorders, infection, angina or Grade 3 or 4 cardiac problems as defined by the New York Heart Association Criteria.
  • Patients with other malignant disorders.
  • Patient with acute or known chronic liver disease (i.e., chronic active hepatitis, cirrhosis).
  • Patients who are known to be HIV positive (no specific tests are required for confirmation of eligibility).
  • Expected incompliance according to treatment, treatment diary and examination schedule
  • Not confirmed histological diagnosis glioblastoma multiforme/astrocytoma WHO grade IV
  • Other drugs with potential cytostatic main or side effect
  • No or inadequate chemotherapy or irradiation therapy
  • Patients without hematological recovery after previous chemotherapy who have been treated with Chemotherapy within 28 days of the first day of administration of study drug.

Other protocol-specific inclusion /exclusion criteria may apply.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00154375

Layout table for location information
Novartis Investigative Site
Duelmen, Germany
Sponsors and Collaborators
Novartis Pharmaceuticals
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Layout table for additonal information
Responsible Party: External Affairs, Novartis Pharmaceuticals Identifier: NCT00154375    
Other Study ID Numbers: CSTI571BDE40
First Posted: September 12, 2005    Key Record Dates
Results First Posted: February 2, 2011
Last Update Posted: April 26, 2011
Last Verified: April 2011
Keywords provided by Novartis:
Open label
Imatinib mesylate
protein tyrosine kinases
glioblastoma multiforme
brain tumor
brain cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Imatinib Mesylate
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antisickling Agents
Nucleic Acid Synthesis Inhibitors